Naproxen Articles
Albemarle's Naproxen
22 May 1995
Are OTC Makers Targeting The Right markets?
8 May 1995
Faulding Hopes For FDA Approval
24 April 1995
Naproxen Approval For Zenith
10 April 1995
Roche's Sales Ahead, Profit Growth Expected
23 January 1995
$25 Bill Latin American Pharma Market In 2000
9 January 1995
World Immunology, Rheumatology Markets
28 November 1994
Syntex Gains Approval For EC-Naprosyn
31 October 1994
Mylan Receives Two Product Approvals
26 September 1994
First-Quarter Results Strong From Elan
5 September 1994
Aleve, Advil Dispute Blows Up
22 August 1994
Generic Drug Stocks - A Buying Opportunity
22 August 1994
Rx-to-OTC Switching Trends
22 August 1994
NAPROXEN AGREEMENT
8 August 1994
WHAT FUTURE FOR STERLING HEALTH
4 July 1994
US FDA URGED TO ACCEPT FOREIGN DATA FOR OTCS
27 June 1994
THE CHANGING US ANALGESIA MARKET
27 June 1994
SYNTEX' 3rd QTR NET PLUNGES 45%
20 June 1994
SYNTEX' 3rd QTR NET PLUNGES 45%
20 June 1994
EUROPEAN PHARMA ISSUES ASSESSED BY IMS
30 May 1994
ETODOLAC AND GI INJURY
23 May 1994
WEST POINT EXPANDS PRODUCT LINE
9 May 1994
GENERIC DRUGS AND DELIVERY SYSTEMS
18 April 1994
BUY RECOMMENDATION FOR TEVA STOCK
11 April 1994
NEW YORK STOCK COMMENT
4 April 1994
GENERIC COMPETITION HITS SYNTEX
7 March 1994
THE FUTURE FOR THE US DRUG MARKET
28 February 1994
SEARLE SIGNS CHINESE AGREEMENT
21 February 1994
MIGRAINE MARKET SET TO BLOSSOM
21 February 1994
UPS AND DOWNS FOR COPLEY PRODUCTS
7 February 1994
SYNTEX FOCUSES EURO PRODUCTION IN SPAIN
7 February 1994
BRAND EQUITY IN THE OTC DRUG MARKET
7 February 1994
CIBA LAUNCHES CATAFLAM NSAID IN USA
31 January 1994
SYNTEX CHIEF SPEAKS ON PRODUCT PROSPECTS
24 January 1994
FIRST OTC NAPROXEN CLEARED FOR SALE
17 January 1994
LIKELY IMPACT ON DRUG FIRMS OF ITALIAN REFORMS
17 January 1994
WORLD ARTHRITIS MARKET FORECAST
20 December 1993
NAPROXEN OTC SWITCH REJECTION EXAMINED
13 December 1993
SYNTEX EXPECTS PATENT EXPIRY EFFECTS
13 December 1993
MUSCULOSKELETAL MARKET TO DECLINE
6 December 1993
103% NET INCOME RISE FOR ISRAEL's TEVA
22 November 1993
US PRODUCT NEWS IN BRIEF
25 October 1993
HOECHST CELANESE ACQUIRES US GENERICS CO
25 October 1993
NEW YORK STOCK COMMENT
20 September 1993
HAMILTON RECEIVES ANDA APPROVAL
13 September 1993
MYLAN'S NAPROXEN APPROVED IN USA
13 September 1993
BULGARIA - SUCCESS FOR NIHFI LTD
13 September 1993
SELF MEDICATION TO PASS $27BILLION IN MAJOR MARKETS
23 August 1993
DRUG IND: CHANGING COST STRUCTURES
2 August 1993
MISOPROSTOL PRAISED AT ILAR
26 July 1993
GOOD OUTLOOK FOR ISRAEL'S TEVA
26 July 1993
APOTEX FACES FBI ACCUSATIONS
12 July 1993
TEVA CORPORATE DEVELOPMENTS
5 July 1993
SMITHKLINE BEECHAM CORPORATE OTC STRATEGY
5 July 1993
NEW YORK STOCK COMMENT
14 June 1993
IMPLICATIONS OF NAPROXEN STALL
14 June 1993
NAPROXEN DENIED OTC STATUS IN USA?
7 June 1993
SYNTEX PROFITS HIT BY RESTRUCTURING
7 June 1993
RECORDATI REFOCUSES; NEW DRUGS OUT SOON
24 May 1993
SYNTEX' NAPROSYN S/R
5 April 1993
SYNTEX ACQUIRES LICENSE
22 March 1993
SYNTEX SHIFTS PLANT TO PUERTO RICO
1 March 1993
CASSENNE LAUNCHES NAPROSYNE IN FRANCE
8 February 1993
1ST LAUNCH OF ARTHROTEC IN UK
8 February 1993
FDA APPROVES 26 NEWDRUGS IN 1992
25 January 1993
US OTC ANALGESICS - A 1992 RETROSPECTIVE
4 January 1993
NEW YORK STOCK COMMENT
7 December 1992
RPSGB CANDIDATES FOR POM-TO-P SWITCHING
2 November 1992
RX-TO-OTC SWITCHING FOR SUCCESS
2 November 1992
ANALYST'S ESTIMATES OF US THIRD QTR EARNINGS
12 October 1992
ELAN CORP FUTURE LOOKS BETTER THAN EXPECTED
3 August 1992
SYNTEX INVESTMENT FOR FUTURE GROWTH
29 June 1992
US NEW PRESCRIPTI0N DRUG SALES IN 1991
13 April 1992
VOLUME GROWTH FOR US DRUGMAKERS
9 March 1992
SYNTEX "A COMPANY ON THE MOVE"
20 January 1992
STOCK MARKET COMMENTARY: NEW YORK
20 January 1992
ANALGESICS IN THE USA -- AN OPEN DOOR FOR P&G?
6 January 1992
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
